Kymera director granted options on 6,068 shares

Kymera Therapeutics, Inc. director Bruce Booth received a grant of stock options covering 6,068 shares of common stock.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director Bruce Booth received a grant of stock options covering 6,068 shares of common stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.

These options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. Following this grant, Booth holds options for 6,068 shares. According to the disclosure, proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Grant/Award: 6,068 shares

Grant/Award 1 txn

Insider Booth Bruce

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
2. F2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Key Figures

Option grant size: 6,068 options Exercise price: $99.87 per share Underlying shares: 6,068 shares +3 more

6 metrics

Option grant size 6,068 options Stock Option (Right to Buy) granted to director Bruce Booth

Exercise price $99.87 per share Conversion or exercise price for the stock option

Underlying shares 6,068 shares Common stock underlying the granted option

Post-grant holdings 6,068 derivative securities Total options held by Booth following this transaction

Vesting date trigger June 24, 2027 Earlier vesting trigger, or next annual stockholder meeting date

Expiration date June 23, 2036 Option expiration for the stock option grant

Key Terms

Stock Option (Right to Buy), pecuniary interest, Section 16 of the Securities Exchange Act of 1934, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

annual meeting of the Issuer's stockholders financial

"earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Bruce Booth?

Kymera reported a stock option grant to director Bruce Booth for 6,068 underlying common shares. The options were awarded at an exercise price of $99.87 per share and represent equity-based compensation rather than an open-market share purchase or sale.

What are the vesting terms of Bruce Booth’s new Kymera (KYMR) stock options?

The stock options granted to Bruce Booth vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. This single-vesting schedule ties his equity award to continued board service through that future event.

What is the exercise price and expiration date of Bruce Booth’s Kymera (KYMR) options?

Bruce Booth’s stock options have an exercise price of $99.87 per share and an expiration date of June 23, 2036. He can choose to exercise and acquire common shares at this price any time after vesting and before expiration under the award’s terms.

How many Kymera (KYMR) shares are covered by Bruce Booth’s new stock option award?

The option grant covers 6,068 shares of Kymera common stock as the underlying security. After this award, Booth’s reported holdings in this option series total 6,068 derivative securities, all related to the same number of potential common shares upon exercise.

Who receives proceeds if Bruce Booth exercises and later sells Kymera (KYMR) shares?

The filing states that proceeds from any sale of Kymera common stock issued upon option exercise will be transferred to Atlas Venture Life Science Advisors, LLC. Booth disclaims ownership of the securities except for any pecuniary interest he may have in those proceeds.

Does this Kymera (KYMR) Form 4 show Bruce Booth buying or selling stock on the market?

The Form 4 reports a grant of stock options as compensation, not an open-market buy or sell transaction. It records an acquisition of derivative securities with a future right to buy Kymera common shares at a fixed price, subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D(2)

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

	/s/ Ommer Chohan, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)